Inhibrx said its OX40 agonist produced clinical responses in patients with head and neck cancer, with the most striking activity appearing in a subset of HPV-positive tumors. The company highlighted the readout as a first win for a long-sought immunotherapy target that has repeatedly failed to deliver durable benefit in prior attempts. CEO Mark Lappe said the program has been shaped by repeated setbacks across the OX40 space, framing the result as a meaningful proof point while also acknowledging the potential limitation of response being concentrated in HPV-positive disease. The company’s data also feed into its combination strategy, including plans to move OX40 agonist studies alongside cancer vaccines for tumors with lower immunogenicity. The next phase for Inhibrx is likely to focus on patient selection, combination rationale, and how to broaden efficacy beyond the HPV-positive subgroup highlighted in the interim results.